On April 18, PharmaEssentia Corp., a leading biopharmaceutical company, completed its $462.7 million offering of global depositary shares (GDS)—marking the largest-ever overseas offering of this kind by a Taiwanese biotech company. The GDSs are traded on the Euro MTF market of the Luxembourg Stock Exchange.
PharmaEssentia develops and distributes therapeutic products for treatment in MPN and other hematology and oncology diseases. The company’s self-developed proprietary lead product, BESREMi®, has been approved in 29 jurisdictions, including the United States, E.U. and Japan, for polycythemia vera treatment.
The S&C team advising Citigroup, J.P. Morgan, Morgan Stanley, Macquarie, UBS and Yuanta as initial purchasers of the GDS offering included Ching-Yang Lin, Stephen Pang, Hanzhi Wang, Henry Wong, and Hester Choi. Jeffrey Hochberg, Saul Brander and Tristan Hood advised on tax matters. Frederick Wertheim advised on 40 Act issues.
Subscribe to stay current on S&C Insights.
Sending an e-mail through this web site does not create an attorney-client relationship. You should not send us any information through this web site that you would want treated confidentially.